Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to $205492.0.

  • HCW Biologics' Share-based Compensation fell 1159.12% to $205492.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 749.33%. This contributed to the annual value of $1.0 million for FY2024, which is 52.42% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Share-based Compensation is $205492.0, which was down 1159.12% from $278307.0 recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Share-based Compensation peaked at $349097.0 during Q4 2021, and registered a low of $1660.0 during Q3 2021.
  • Its 5-year average for Share-based Compensation is $249597.0, with a median of $261272.0 in 2023.
  • As far as peak fluctuations go, HCW Biologics' Share-based Compensation surged by 1811204.82% in 2022, and later tumbled by 2727.97% in 2023.
  • Quarter analysis of 5 years shows HCW Biologics' Share-based Compensation stood at $349097.0 in 2021, then decreased by 18.02% to $286188.0 in 2022, then decreased by 8.71% to $261272.0 in 2023, then increased by 11.79% to $292071.0 in 2024, then dropped by 29.64% to $205492.0 in 2025.
  • Its Share-based Compensation stands at $205492.0 for Q3 2025, versus $278307.0 for Q2 2025 and $275642.0 for Q1 2025.